Comment by BothZookeepergame612 on 03/02/2025 at 19:55 UTC

10 upvotes, 1 direct replies (showing 1)

View submission: Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Extremely positive news for once...

Replies

Comment by AcornAl at 04/02/2025 at 01:50 UTC

6 upvotes, 0 direct replies

Results for pemivibart are fairly positive, so one can assume VYD2311 should be better, but probably premature to consider this as an alternative for vaccinations from a small trial with 40 people.

In Australia and the UK, we don't even recommend vaccinations to non-risk groups anymore due to the high cost, so it would be hard to see them recommending something else with a similar $/QALY. Possibly a great alternative for those that are immunosuppressed and potentially a treatment option?

• As an aside, I wonder what companies design drugs to be a non-superior alternative to existing products. You have to love shareholder media releases. ;)*